Telomir Pharmaceuticals (NASDAQ: TELO) announced the peer-reviewed publication of preclinical data in Biomedicine & Pharmacotherapy demonstrating that its lead candidate, Telomir-Zn, restored insulin sensitivity and improved glucose homeostasis in a diet-induced zebrafish model of Type 2 diabetes. The study showed that treatment produced dose-dependent reductions in fasting blood glucose and insulin levels, improved glucose tolerance, and significantly lowered HOMA-IR scores, a widely used measure of insulin resistance.
The findings add to a growing body of evidence supporting Telomir-Zn’s mechanism of action through modulation of intracellular metal homeostasis. According to the company, the biological pathways targeted by Telomir-Zn have been implicated in both metabolic disease and cancer. The results complement Telomir’s recently FDA-cleared Phase 1/2 clinical program evaluating the drug in patients with advanced or metastatic triple-negative breast cancer.
For investors, this news matters because it expands the therapeutic potential of Telomir-Zn beyond oncology into metabolic disorders like Type 2 diabetes, which affects hundreds of millions worldwide. If the preclinical results translate to humans, Telomir-Zn could address a major unmet need in diabetes treatment, where many patients fail to achieve adequate glycemic control with existing therapies. The dual activity in cancer and metabolic disease also suggests a broad platform opportunity, potentially increasing the company’s valuation and partnering prospects.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
The full press release is available at https://ibn.fm/BoK2F. For the latest news and updates relating to TELO, visit the company’s newsroom at https://ibn.fm/TELO.
